| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S2007-Breast, Brain Mets, Sacituzumab Govitecan | Y | ALLIANCE | 7 | ||
| ECOG-ACRIN | 3 | |||||
| SWOG | 18 | |||||
| sum | 28 | |||||
| S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | Y | ALLIANCE | 20 | |||
| ECOG-ACRIN | 25 | |||||
| NRG | 11 | |||||
| SWOG | 79 | |||||
| sum | 135 | |||||
| S2212-Breast, TNBC, Neoadj Chemo + Pembro | Y | ALLIANCE | 111 | |||
| ECOG-ACRIN | 92 | |||||
| NRG | 67 | |||||
| SWOG | 280 | |||||
| sum | 550 | |||||
| CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 18 | ||
| ECOG-ACRIN | 28 | |||||
| NRG | 20 | |||||
| SWOG | 330 | |||||
| sum | 396 | |||||
| S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship | 16-DEC-24 | N | ALLIANCE | 19 | ||
| ECOG-ACRIN | 31 | |||||
| NRG | 16 | |||||
| SWOG | 265 | |||||
| sum | 331 | |||||
| S2108CD-Genomic Tumor Board vs Usual Practice | 22-NOV-24 | N | ALLIANCE | 81 | ||
| ECOG-ACRIN | 63 | |||||
| SWOG | 1140 | |||||
| sum | 1284 | |||||
| ERLYTX | EAY191-S3-ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | Y | ALLIANCE | 1 | ||
| ECOG-ACRIN | 7 | |||||
| NRG | 1 | |||||
| SWOG | 6 | |||||
| sum | 15 | |||||
| S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo | Y | ALLIANCE | 14 | |||
| ECOG-ACRIN | 9 | |||||
| NRG | 9 | |||||
| SWOG | 55 | |||||
| sum | 87 | |||||
| GI | S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | ALLIANCE | 12 | ||
| ECOG-ACRIN | 2 | |||||
| NRG | 3 | |||||
| SWOG | 24 | |||||
| sum | 41 | |||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | Y | ALLIANCE | 6 | |||
| ECOG-ACRIN | 16 | |||||
| NRG | 8 | |||||
| SWOG | 37 | |||||
| sum | 67 | |||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | Y | ALLIANCE | 5 | |||
| ECOG-ACRIN | 8 | |||||
| NRG | 8 | |||||
| SWOG | 43 | |||||
| sum | 64 | |||||
| S2107-Colorectal, BRAF mut, Enc + CET +/-Nivo | 30-SEP-24 | N | ALLIANCE | 8 | ||
| ECOG-ACRIN | 14 | |||||
| NRG | 10 | |||||
| SWOG | 56 | |||||
| sum | 88 | |||||
| S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | Y | ALLIANCE | 7 | |||
| NRG | 1 | |||||
| SWOG | 11 | |||||
| sum | 19 | |||||
| GU | S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | Y | ALLIANCE | 114 | ||
| ECOG-ACRIN | 97 | |||||
| NRG | 108 | |||||
| SWOG | 574 | |||||
| sum | 893 | |||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | ALLIANCE | 7 | |||
| ECOG-ACRIN | 14 | |||||
| NRG | 14 | |||||
| SWOG | 84 | |||||
| sum | 119 | |||||
| S1937-Blad, Mets, Eribulin + Gem vs SOC | Y | ALLIANCE | 5 | |||
| ECOG-ACRIN | 12 | |||||
| NRG | 2 | |||||
| SWOG | 63 | |||||
| sum | 82 | |||||
| S2200-pRCC, Adv, Cabo ± Atezo | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 4 | |||||
| NRG | 4 | |||||
| SWOG | 21 | |||||
| sum | 31 | |||||
| S2210-Pros, High Risk, BRCA, Neoadj Carbo | Y | SWOG | 4 | |||
| sum | 4 | |||||
| LEUK | MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental | Y | ALLIANCE | 1 | ||
| ECOG-ACRIN | 2 | |||||
| NRG | 1 | |||||
| SWOG | 9 | |||||
| sum | 13 | |||||
| MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials | Y | ALLIANCE | 98 | |||
| CCTG | 26 | |||||
| ECOG-ACRIN | 85 | |||||
| NRG | 14 | |||||
| SWOG | 170 | |||||
| sum | 393 | |||||
| S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 2 | |||||
| SWOG | 15 | |||||
| sum | 19 | |||||
| S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | ALLIANCE | 31 | |||
| CCTG | 12 | |||||
| ECOG-ACRIN | 17 | |||||
| NRG | 5 | |||||
| SWOG | 73 | |||||
| sum | 138 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 869 | ||
| ECOG-ACRIN | 364 | |||||
| NRG | 496 | |||||
| SWOG | 1862 | |||||
| sum | 3591 | |||||
| S1827-SCLC, MRI Surveillance +/- PCI | Y | ALLIANCE | 24 | |||
| CCTG | 33 | |||||
| ECOG-ACRIN | 10 | |||||
| NRG | 78 | |||||
| SWOG | 124 | |||||
| sum | 269 | |||||
| S1900E-KRAS G12C: Sotorasib (AMG 510) | 27-DEC-24 | N | ALLIANCE | 21 | ||
| ECOG-ACRIN | 19 | |||||
| NRG | 12 | |||||
| SWOG | 66 | |||||
| sum | 118 | |||||
| S1900G-EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | Y | ALLIANCE | 3 | |||
| NRG | 3 | |||||
| SWOG | 12 | |||||
| sum | 18 | |||||
| S1900J-MET Amplification: Amivantamab-SC | Y | ALLIANCE | 1 | |||
| sum | 1 | |||||
| S1900K-MET Exon 14: Tepotinib +/- Ramucirumab | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 2 | |||||
| sum | 3 | |||||
| S1933-NSCLC, Stg II-III, RT + Atezo | Y | ALLIANCE | 5 | |||
| NRG | 1 | |||||
| SWOG | 37 | |||||
| sum | 43 | |||||
| S2302-NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | 20-DEC-24 | N | ALLIANCE | 154 | ||
| ECOG-ACRIN | 90 | |||||
| NRG | 55 | |||||
| SWOG | 539 | |||||
| sum | 838 | |||||
| LYMPH | S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | Y | ALLIANCE | 42 | ||
| ECOG-ACRIN | 17 | |||||
| NRG | 7 | |||||
| SWOG | 70 | |||||
| sum | 136 | |||||
| S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | Y | ALLIANCE | 23 | |||
| ECOG-ACRIN | 9 | |||||
| NRG | 5 | |||||
| SWOG | 81 | |||||
| sum | 118 | |||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | Y | ALLIANCE | 5 | |||
| NRG | 4 | |||||
| SWOG | 18 | |||||
| sum | 27 | |||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | Y | ALLIANCE | 18 | |||
| ECOG-ACRIN | 6 | |||||
| NRG | 2 | |||||
| SWOG | 31 | |||||
| sum | 57 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 222 | ||
| CCTG | 21 | |||||
| ECOG-ACRIN | 186 | |||||
| NRG | 115 | |||||
| SWOG | 783 | |||||
| sum | 1327 | |||||
| S2005-WM, Prev. Untreated, I/R +/- Venetoclax | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 8 | |||||
| NRG | 1 | |||||
| SWOG | 2 | |||||
| sum | 12 | |||||
| S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | Y | ALLIANCE | 8 | |||
| ECOG-ACRIN | 4 | |||||
| NRG | 4 | |||||
| SWOG | 53 | |||||
| sum | 69 | |||||
| S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | Y | ALLIANCE | 2 | |||
| SWOG | 9 | |||||
| sum | 11 | |||||
| MULT | S2101-Melan or HNSCC, Adv, Cabo + Nivo | Y | ALLIANCE | 8 | ||
| ECOG-ACRIN | 7 | |||||
| NRG | 5 | |||||
| SWOG | 34 | |||||
| sum | 54 | |||||
| PEOLC | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 43 | ||
| SWOG | 235 | |||||
| S1501 | Y | ALLIANCE | 27 | |||
| NRG | 27 | |||||
| sum | 332 | |||||
| SXQOL | S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed | 15-JAN-25 | N | ALLIANCE | 42 | |
| ECOG-ACRIN | 37 | |||||
| NRG | 87 | |||||
| SWOG | 399 | |||||
| sum | 565 | |||||
| S2013-I-CHECKIT: ICI toxicity risk prediction study | Y | ALLIANCE | 355 | |||
| ECOG-ACRIN | 114 | |||||
| NRG | 260 | |||||
| SWOG | 1424 | |||||
| sum | 2153 | |||||
| S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | Y | ALLIANCE | 55 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 83 | |||||
| SWOG | 183 | |||||
| sum | 326 | |||||